The End of the Billion-Dollar Drug

AbbVie’s Humira, the most financially successful drug in history, will be saying goodbye to its 20-year throne of U.S. market exclusivity. That’s 20 years of zero competition in the U.S. Following years of lawsuits and AbbVie’s patent tactics, several Humira biosimilars will hit the market throughout the year, with the first one by Amgen hitting the market…

Read More

Big Banks’ Next Big Bet

The big fintech news this week is that Early Warning Services (EWS) – a consortium of seven big U.S. banks – is developing a digital wallet: Wells Fargo, Bank of America, JPMorgan Chase, and four other banks are working on a new product that will allow shoppers to pay at merchants’ online checkout with a…

Read More

Taking the Leap: How to Transition from Short Term to Long Term Thinking

There are so many differences between creating a company and starting a venture fund; it’s hard to figure out where to start. The work is different but so is the thinking and the mindset you need to have to be successful. Something I’ve noticed is shifting my thinking from short term to long term. As…

Read More

CBInsights’ Q4 Fintech Investing Summary

2022 was a very weird for the whole tech industry, but it was particularly challenging for VC’s. In the public markets, valuations for tech companies were getting slashed left and right—VC’s needed to figure out how that affected the private markets. And fintech was one of the hardest hit sectors—valuations fell dramatically and VC dollars…

Read More